StreetAlpha.app
Home › Stocks › STRO

Sutro Biopharma, Inc. (STRO)

Healthcare
$8.92
▼ −4.29%
LAST CLOSE · NOV 17

Sutro Biopharma develops antibody drug conjugates, a type of cancer treatment, for patients with solid tumors. It last closed at $8.92 on Nov 17, down 4.29% on the day.

AI Auto Pilots
Is STRO in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$45.1M
−57.3% vs a year ago
Net income
−$155.3M
−344.2% margin
EPS (diluted)
−$12.49
Operating margin
−265.0%
−$119.5M operating income
Valuation
Market cap
$148.1M
16.6M shares
P/E
–
No P/E while losing money
Price to sales
3.3
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$46.9M
At Sep 30
Shareholder equity
−$132.5M
Shares outstanding
16.6M
At Nov 6
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $61.9M$61.9MFY2021FY2022: $67.8M$67.8MFY2022FY2023: $153.7M$153.7MFY2023FY2024: $62.0M$62.0MFY2024FY2025: $102.5M$102.5MFY2025

From STRO's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 12). Last 12 months adds up the four latest quarters.

Last report
Nov 12
2026 · next date not on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
1 Buy
1 firm · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
1 Buy
1firm
1 Buy0 Hold0 Sell
Only 1 firm rated STRO in the past 90 days, not enough for a consensus
Average 12-month target
$57.00
▲ 539.0% upside

Based on 1 analyst who set a price target on STRO in the past 90 days. The average target is $57.00, with a high of $57.00 and a low of $57.00, compared with the last close of $8.92.

Low $57.00Avg $57.00High $57.00
Blue marker: last close $8.92
Highest target$57.00
Average target$57.00
Lowest target$57.00
Latest rating changes
BarclaysTarget raised
Nov 13Buy$56 → $57
CitizensMaintained
Aug 13Buy$34
WedbushReiterated
Aug 13Buy$60
Truist SecuritiesAssumed coverage
Jun 11Buy$50
BarclaysInitiated
May 28Buy$56
DateFirmActionRatingPrice target
Nov 13BarclaysTarget raisedBuy$56 → $57
Aug 13CitizensMaintainedBuy$34
Aug 13WedbushReiteratedBuy$60
Jun 11Truist SecuritiesAssumed coverageBuy$50
May 28BarclaysInitiatedBuy$56
Loading…

Technical Analysis

STRO · as of the Nov 17 close · updated after every close
Downtrend, nearing oversold

The stock is 7% below its 20 day and 43% below its 50 day average. It is 154% below its 200 day average, so the longer trend is down. Momentum is fading (RSI 35), near oversold. The nearest support is the swing low (Nov 3) at $8.79, and the nearest resistance the Pivot at $8.98.

Short trendBearish
Long trendBearish
MomentumFading
StretchNear oversold
VolatilityNormal, 10.9%/day
Key levels
$43.8552 week high+391.6%
$22.70200 day average+154.5%
$18.56100 day average+108.1%
$12.7650 day average+43.0%
$10.74Swing high (Nov 9)+20.4%
$9.5920 day average+7.5%
$9.30Pivot R1+4.3%
$8.98Pivot+0.7%
$8.92Last close
$8.79Swing low (Nov 3)−1.5%
$8.60Pivot S1−3.6%
$7.1552 week low−19.8%
Indicators
RSI (14)35.03Weak, oversold below 30Neutral
MACD-0.95Above its signal lineBullish
Stochastic41.7Middle of its rangeNeutral
ADX (14)46.2Strong downtrend
Williams %R-75.8Oversold below −80, overbought above −20Neutral
CCI (20)-82.7Oversold below −100, overbought above 100Neutral
Rate of change−6.2%Change over 10 sessionsBearish
ATR (14)$0.97Typical daily range, 10.9% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for STRO

What happened before

See how STRO did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow STRO usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How STRO has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2018.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in STRO in the last 90 days.

Loading…

See today’s whale options flow across the market →

STRO Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲54 buying vs 43 selling
  • ▲Held by funds +1.3 pts
  • ▲Funds holding +7
  • ●Superinvestors: 2 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding107100+7.0%
In funds' top 1025−60.0%
Held by funds100.6%99.3%+1.3 pts
New / increased23 / 3141 / 24−16.9%
Reduced / sold out27 / 1618 / 18+19.4%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See STRO institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether STRO is in one of them and how their past STRO trades turned out.

STRO in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered STRO in an article yet. Here's the latest on the wider market.

About Sutro Biopharma

Sutro Biopharma develops antibody drug conjugates, or ADCs, which are cancer treatments that link antibodies to cell-killing drugs. It uses its XpressCF protein synthesis platform to make these protein therapies, mainly for cancers. Its lead candidate, STRO-004, is in clinical trials for solid tumors. The company also works with pharmaceutical and biotechnology companies in oncology through research collaborations, and it is based in South San Francisco, California.

Headquarters
South San Francisco, CA
Founded
2003